



1645

## **TECH CENTER 1600/2900**

**PATENT** 

Attorney Docket No. CYM-036 (2174/48)



### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S):

Lentrichia et al.

SERIAL NO.:

10/053,349

**GROUP NO.:** 

1645

FILING DATE:

January 15, 2002

**EXAMINER:** 

Not Yet Assigned

TITLE:

Nucleic Acid Extraction Solution and Use Thereof

### CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, is/are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to the Commissioner for Patents, Washington, DC 20231 on this 22<sup>nd</sup> day of November, 2002.


Diane Racicot

Commissioner for Patents Washington, D.C. 20231

Sir:

### Submitted herewith are:

- 1. Transmittal Form (1 page);
- 2. Information Disclosure Statement (2 pages);
- 3. Form PTO-1449 (1 page);
- 4. Cited References A1, A2, C1-C8;
- 5. and a return receipt postcard.



Patent Administrator

Testa, Hurwitz & Thibeault, LLP

High Street Tower 125 High Street

Boston, MA 02110

Tel. No.: (617) 248-7000 Fax No.: (617) 248-7100

Date: November 22, 2002 Reg. No. (Limited Recognition)

Tel. No.: (617) 248-7808

Fax No.: (617) 248-7100

Duan Wu

Attorney for Applicant

Testa, Hurwitz & Thibeault, LLP

High Street Tower 125 High Street Boston, MA 02110



# PATENT Attorney Docket No. CYM-036 (2174/48)

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

DEC 0 2 2002

APPLICANT(S):

Lentrichia et al.

TECH CENTER 1600/2900

SERIAL NO.:

10/053,349

**GROUP NO.:** 

1645

FILING DATE:

January 15, 2002

EXAMINER:

Not Yet Assigned

TITLE:

Nucleic Acid Extraction Solution and Use Thereof

Commissioner for Patents Washington, D.C. 20231

### INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patents and publications are enclosed.

### **REMARKS**

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

(1)	within three (3) months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. 1.114; or
(2)	after the period defined in (1) but before the mailing date of a final action or a notice of allowance under 37 C.F.R. 1.311, and
	the requisite Statement is below, OR
	the requisite fee under 37 C.F.R. 1.17(p), namely \$180.00, is included herein, or
(3)	after the mailing date of a final action or notice of allowance but before the payment of the issue fee, AND

Information Disclosure Statement Serial No. 10/053,349 Page 2 of 2

the requisite Statement is below, AND
the requisite petition fee under 37 C.F.R. 1.17(p), namely \$180.00 is included herein

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

#### **STATEMENT**

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:

- Each item of information contained in the Information Disclosure Statement was 1. first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement; or
- No item of information contained in the Information Disclosure Statement was 2. cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

Respectfully submitted,

Date: November 22, 2002

Reg. No. (Limited Recognition)

Tel. No.: (617) 248-7808 Fax No.: (617) 248-7100

2293568

Duan Wu

Attorney for Applicants

Testa, Hurwitz, & Thibeault, LLP

**High Street Tower** 125 High Street

Boston, Massachusetts 02110

EORM PTO - 1449 SAFORMATION DISCLOSURE STATEMENT

ATTORNEY DOCKET NO.: CYM-036

APPLICANT(S): Lentrichia et al

SERIAL NO.: 10/053,349

RECEIVED

DEC 0 2 2002

1600/2900

				FILING DAT			2 GRO	JUP: 164	13   E	CH CENT		
			U.S	S. PATENT I	DOCUM	ENTS			,			
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME			CLASS	SUB CLASS	FILING DATE IF APPROPRIATE			
	A1	2,748,171	5/29/56	Finch et al.								
	A2	5,942,391	8/24/99	Zhang et al.								
			FORE	IGN PATEN	T DOCU	MENTS						
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CLASS		SUB CLASS	FILING DATE	ABSTRACT ONLY		ENGLISH LANG (Y/N)		
			OTHER	DT. IOUDN	AL ADT	IOLEG E	TC					
	T			RT, JOURN	-	•						
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)											
	Cl Austin et al., "Extraction and PCR of DNA From Parasitoid Wasps That Have Been Chemically I Australian Journal of Entomology, Vol. 36, 1997, pp. 241-244.											
	C2 Boom et al., "Rapid and Simple Method for Purification of Nucleic Acids" <u>Journal of Clinical Microvol.</u> 28, No. 3, March 1990, pp. 495-503.  C3 Fanson et al., "A Comparison Between the Phenol-Chloroform Method of RNA Extraction and The Viral RNA Kit in the Extraction of Hepatitis C and GB Virus-C/Hepatitis G Viral RNA From Serun <u>Journal of Virological Methods</u> , Vol. 89, 2000, pp. 23-27.									Microbiology		
	C4	Forbes et al., "Substances Interfering with Direct Detection of <i>Mycobacterium tuberculosis</i> in Clinical Specimens by PCR: Effects of Bovine Serum Albumin" <u>Journal of Clinical Microbiology</u> , Vol. 34, No. 9, September 1996, pp. 2125-2128.										
	C5	Gossack et al., "Use of DNA Purification Kits for Polymerase Chain Reaction Testing of Gen-Probe Chlamydia trachomatis PACE 2 Specimens" <u>Sexually Transmittal Diseases</u> , Vol. 25, No. 5, May 1998, pp. 265-271.										
	C6	Lentrichia et al., "Detection of <i>C. trachomatis</i> from the ThinPrep Pap Test Using Rapid Extraction and Thermocyling with Real-Time Detection by Molecular Beacons" <u>International Congress of Sexually Transmitted Infections ISSTDR/IUSTI</u> , June 24-27, 2001, pp. 67-73.										
	C7	Sambrook et al., "Isolation of DNA from Mammalian Cells: Protocol I & II," Molecular Cloning a Laboratory Manual, 1989, § 9.16-9.23 (2d Ed.).										
	Walsh et al., "Chelex ® 100 as a Medium for Simple Extraction of DNA for PCR-Based Typing fit Forensic Material" <u>BioTechniques</u> , Vol. 10, No. 4, 1991, pp. 506-513.											
EXAMI	MED				DATE CO	ONSIDERI	en.	****				